

CURRICULUM VITAE

LAST NAME : TAGLIALATELA
FIRST NAME : MAURIZIO
PLACE AND DATE OF BIRTH : NAPLES, ITALY - May 18, 1961
NATIONALITY : ITALIAN
MARITAL STATUS : Married

PRESENT POSITION : Professor of Pharmacology

ADDRESS : Dept. Neuroscience, School of Medicine, University of Naples Federico II. Via Pansini 5, 80131 Naples, ITALY. Tel +39-081-746-3316 (lab); 3310 (office); fax +39-081-7463323; cell 335-7128298; email mtaglial@unina.it

STUDIES AND ACADEMIC CAREER

2020-... Director of the Clinical Pharmacology Unit, Federico II University Hospital, Naples, IT

2018-... Coordinator, PhD Program in Neuroscience, University of Naples Federico II, Naples, IT

2017-2019 Director of the Clinical Program in "Pharmacogenomics in Drug Efficacy and Toxicity", Department of Clinical Neuroscience, Anesthesiology, and Drug Utilization, Federico II University Hospital, Naples, IT

2017-2018 Committee Member, PhD Program in Neuroscience, University of Naples Federico II, Naples, IT

2016-... Professor of Pharmacology, Department of Neuroscience, School of Medicine, University of Naples Federico II, Naples, IT

2014-2017 Coordinator, PhD Program in Translational and Clinical Medicine, University of Molise and IRCCS Neuromed, Campobasso, IT.

2011-2016 Scientific Director of the Center for Pharmacovigilance of the Regione Molise, Campobasso, IT

2013-2016 Chairman of the Center for Higher Education of Public and Private Management of the University of Molise, Campobasso, IT (Unimol Management)

2005-2012 Dean, Faculty of Health Science, University of Molise, Campobasso, IT

2004-2016 Professor of Pharmacology, Faculty of Health Science, University of Molise, Campobasso, IT

1998-2004 Associate Professor of Pharmacology, Department of Neuroscience of the University of Naples Federico II, Faculty of Medicine, Naples, IT

1995-1998 Assistant Professor of Pharmacology, Department of Neuroscience of the University of Naples Federico II, Faculty of Medicine, Naples, IT

1990-1995 Research Assistant and Research Assistant Professor, Department of Molecular Physiology and Biophysics of Baylor College of Medicine, Houston, TX, USA.

1992 PhD in Cellular and Molecular Biology and Pathology. Dept. of Cellular and Molecular Biology and Pathology. University of Naples Federico II.

1985 Medical Degrees (110/110 cum laude). University of Naples Federico II, Naples, IT.

PROFESSIONAL ABILITIES

REFERENCE PHARMACOLOGIST AT PHASE I CLINICAL TRIAL SITES (latest GCP training, November 9-10, 2020)

- IRCCS Fondazione "G. Pascale", Naples, ITALY
- Trial EudraCT: 2016-002328-10 (TIGEM1-MPSVI) at the Department of Medical and Translational Science – Section of Pediatrics, of the Federico II University Hospital, Naples, ITALY

INTERNATIONAL RESEARCH EXPERIENCE

- Visiting student, Department of Physiology, University of Virginia, Charlottesville, VA, USA (July 1984-November 1984)
- Research Assistant (March 1st, 1990 - December 31st, 1993) and Research Assistant Professor (January 1st, 1994 - June 30th, 1995) Department of Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, TX, USA
- Ikerbasque Visiting Professor (March 1st, 2013-February 28th, 2014). Unidad de Biofísica. University of the Basque Country. Bilbao, Spain.
- Visiting Professor (April 15th 2018-May 17th 2018), International Workstation of Neuropharmacology, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China

PROJECT AND PEOPLE EVALUATION COMMITTEES IN INTERNATIONAL RESEARCH CENTERS

- Component of the Ramon y Cajal Programme Committee, June 9-13, 2003. Madrid (ES).
- President of the Evaluation Committee for the Doctorado en Bioquímica y Biología Molecular, Universidad del País Vasco, Facultad de Ciencias, Unidad de Biofísica UPV-CSIC, October 24th, 2008. Bilbao (ES).
- Member of the Committee for the Evaluation of Associate and Full Professors in Pharmacology in Italy (ASN BIO/14 (2018-2020)
- Thesis Opponent, PhD of Johan Larsson, Linköping University, Sweden. June 5, 2020.
- Committee Member, Appointment of Professor/Clinical Professor, Faculty of Health Sciences, University of Southern Denmark, DK. April 2020.

REQUEST FOR RECOMMENDATION LETTERS

- Dept. of Anesthesiology, UCLA School of Medicine, Center for the Health Sciences, Los Angeles CA (USA)
- Dept. of Physiology, UCLA School of Medicine, Center for the Health Sciences, Los Angeles CA (USA)
- Department of Physiology, University of Texas Health Science Center at San Antonio, San Antonio TX (USA)
- Dept. of Physiology and Pharmacology, Tel Aviv University, Tel Aviv (IL)
- International School for Advanced Sciences, Trieste (IT)
- Ikerbasque, Basque Foundation for Science, Bilbao (ES)
- Université Claude Bernard/Hospices Civils de Lyon, Lyon (FR).

PARTICIPATION TO INTERNATIONAL RESEARCH COMMITTEES FOR PHARMACEUTICAL DRUG DEVELOPMENT

- Consultant for *Chantest*[®] (Cleveland, OH – USA), a leading International Company for preclinical assessment of the mechanism of action of drugs at the level of ion channels and membrane receptors (since 2002).
- *Consensus Group on Third Generation antihistamines* (CONGA; Chairman: Prof. S. Holgate), coordinator for Panel 3: "Lack of cardiotoxicity", together with Proff. J. Morganroth (Chairman and Chief Scientific Officer, eResearch Technologies, Philadelphia, USA) and P. Potter (Direttore della Division of Allergy, University of Cape Town, South Africa), to define International Guidelines for treatment with second- and third-generation antihistamines (Published as : Holgate S, Canonica G, Simons F, Taglialatela M, Tharp M, Timmerman H, Yanai K. Consensus group on new-generation antihistamines (CONGA): present status and recommendations. *Clin Exp Allergy* 33:1305-1324, 2003).
- *Allegra*[®] in airway inflammation workshop. Advisory Board of international researchers arranged by *Aventis* to define pre-clinical studies aimed to assess the rationale and the mechanism of action of drugs to be used for asthma treatment. New York, NY USA, February 12-13, 2003.
- Advisory Board of international researchers arranged by *Lilly*[®] to develop novel therapies for depression and alcohol dependence. Milano, IT, June 17-18, 2010.
- Advisory Board of international researchers arranged by *Lilly*[®] to develop novel therapies for CV and RA/CKD. Barcelona, ES, February 23-25, 2011.

- Advisory Board of international researchers arranged by *Glaxo-Smith Kline*® to develop novel therapies for epilepsy. Verona, IT, December 13, 2011.
- Advisory Board of international researchers arranged by *Novartis*® to develop novel therapies for Hepatitis C. Zurich, CH, October 16, 2012.

FELLOWSHIPS AND AWARDS

- "Travel Support Fellowship" for young investigators to attend to the 1st International Congress of Neuroendocrinology, San Francisco, CA, USA (9-11 July 1986).
- Fellowship of the University of Naples to attend specialization courses in the academic year 1986-1987.
- "Travel Support Fellowship" for young investigators to attend to the XI Meeting of the European Neuroscience Association, Zurich, Switzerland (4-8 September 1988).
- Fellowship of the Italian Society for Pharmacology as one of the best 5 posters at the XXIV Meeting of the Italian Pharmacological Society, Brescia, Italy (25-28 September 1988).
- Fellowship of the Consiglio Nazionale delle Ricerche to for working experience to be performed in abroad laboratories for the National Committee for Biological and Medical Sciences (1988).
- Fellowship of the NATO-Consiglio Nazionale delle Ricerche to for working experience to be performed in abroad laboratories for the National Committee for Biotechnology and Molecular Biology (1990).
- "Alberico Benedicenti" award of the Italian Society of Pharmacology and the University of Florence for best scientific performance in the 1992 and 1993 years in the field of pharmacology and toxicology.

MEMBERSHIP IN SCIENTIFIC SOCIETES

- Italian Society of Pharmacology (1986- ...)
- Italian Society of Neurosciences (1986- ...; 2005-2009, Member of the Society Council)
- Society for Neuroscience (1990-...)
- Biophysical Society (1993-...).

INVITED SPEAKER AT INTERNATIONAL MEETINGS (>30 times), NATIONAL CONGRESSES (>20 times), AND INTERNATIONAL RESEARCH INSTITUTIONS (10 times).

REFEREE FOR INTERNATIONAL JOURNALS

Annals in Neurology, Proceedings of the National Academy of Sciences, Trends in Pharmacological Sciences, Journal of Neuroscience, Journal of Cell Biology, European Journal of Neuroscience, Journal of Neurochemistry, Journal of Pharmacology and Experimental Therapeutics, Journal of Physiology, American Journal of Physiology, Molecular Pharmacology, Neuropharmacology, British Journal of Pharmacology, Gene, Biophysical Journal, Journal of Medical Genetics, Epilepsia, ...

REFEREE FOR NATIONAL AND INTERNATIONAL RESEARCH PROJECT EVALUATION

- Comitato Promotore Telethon (IT)
- Ministry of Education and Research (IT), call PRIN 2008
- Ministry of Health (IT), call on Rare Diseases 2008
- National Science Foundation (USA)
- Medical Research Council (UK)
- Wellcome Trust Foundation (UK)
- Israeli Science Foundation (IL)
- Ramon y Cajal Programme (ES)
- Georgian Science Foundation (GE)
- European Community (VII Framework Programme) (EU), call on CNS Rare Diseases.
- French National Research Agency (FR)
- Fundação para a Ciência e a Tecnologia (PT)

RECENT INTERNATIONAL COLLABORATIONS

1. Dr. Mark Shapiro, Department of Physiology, University of Texas Health Science Center, San Antonio, TX, USA
2. Dr. Francisco Bezanilla, Dept. of Molecular Pediatrics, University of Chicago, Chicago IL, USA
3. Dr. Gaetan Lesca, Service de génétique moléculaire et Clinique. CHRU de Lyon, Lyon, FRANCE
4. Dr. Alvaro Villarreal, Unidad de Biofísica CSIC, Universidad del País Vasco/EHU, Bilbao, Spain
5. Dr. Edward Cooper, Dept. of Neuroscience, Baylor College of Medicine, Houston TX, USA
6. Dr. Iain Greenwood, Division of Biomedical Sciences, St George's University of London, London, UK
7. Dr. Rym Benkhalifa, Laboratoire des Venins et Molécules Thérapeutiques, Institut Pasteur de Tunis, Tunis-Belvédère, TN
8. Dr. Roberta Cilio, Director of Research in Pediatric Epilepsy, IREC, Université Catholique de Louvain, BE
9. Dr. Johannes Lemke, Institute of Human Genetics, University of Leipzig Hospitals and Clinics, Leipzig, GER

10. Dr. Zhaobing Gao, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China

PRINCIPAL INVESTIGATOR IN NATIONAL AND INTERNATIONAL GRANTS (last 10 years)

- 2008-2011** European Community: "Benign Familial Neonatal Seizures (BFNS) as disease model for human idiopathic epilepsies: expansion of the genotype-phenotype correlations and insights into novel disease mechanisms" (E-rare 2007 call) (coord. Dr. Maria Roberta Cilio, Ospedale Bambin Gesù, Roma - IT).
- 2007-2009** Italian Ministry of Education and Research (MIUR): "Role of specific classes of potassium channels in the analgesic action of endogenous acylethanolamides", Research Unit Coordinator within the National Project "Exploring the functional and pharmacological roles of endogenous acylethanolamides" (coord. Prof. A. Calignano).
- 2010-2011** Compagnia di San Paolo (San Paolo – IMI): "Exploring the molecular mechanisms at distinct neuronal sites underlying the therapeutic potential of leptin in neurodegeneration, epilepsy, and obesity", Neuroscience Project (coord. Prof.ssa V. Carabelli).
- 2012-2014** Province of Avellino "Molecular Basis and Innovative Pharmacological Intervention against Neonatal Epilepsy".
- 2015-2017** Comitato Promotore Telethon: "Genotype-phenotype correlations, novel pathogenetic mechanisms, and pilot clinical studies in neonatal epilepsies associated to mutations in the KCNQ2/3 potassium channel genes".
- 2020-2023** Italian Ministry of Education and Research (MIUR): "Genetic epileptic channelopathies as disease models for drug discovery toward personalized treatment: an integrated bench-to-bedside and backward approach" (National Coordinator).
- 2020-2024** European Commission. "Up-scaling the global univocal identification of medicines" (Bando: H2020-SC1-DTH-2018-2020)
- 2021-2024** Italian Ministry of Health (MoH): Functional-genetic stratification as a guide to personalized treatment in developmental and epileptic encephalopathies due to potassium channel mutations (Coordinator) EJP RD JTC 2020; Call for Proposals 2020 "PRE-CLINICAL RESEARCH TO DEVELOP EFFECTIVE THERAPIES FOR RARE DISEASES": "Targeted treatment for KCNQ related encephalopathies: retigabine analogues, repurposed drugs and allele specific knock down" (TREATKCNQ; Coordinator Prof. Sarah Weckhuysen, University of Antwerp, BE)

BIBLIOGRAPHY (Scopus, accessed on Feb 25, 2021)

Sum of the Times Cited (1984-2017): 7481; h-index: 48

Five most relevant papers in the last 5 years (2015-2020)

1. OSTACOLO C, MICELI F, DI SARNO V, NAPPI P, IRACI N, SOLDVIERI MV, CIAGLIA T, AMBROSINO P, VESTUTO V, LAURITANO A, MUSELLA S, PEPE G, BASILICATA MG, MANFRA M, PERINELLI DR, NOVELLINO E, BERTAMINO A, GOMEZ-MONTERREY IM, CAMPIGLIA P, TAGLIALATELA M. Synthesis and Pharmacological Characterization of Conformationally Restricted Retigabine Analogues as Novel Neuronal Kv7 Channel Activators. **J Med Chem.** 63:163-185, 2020.
2. SANDS TT, MICELI F, LESCA G, BECK AE, SADLEIR LG, ARRINGTON DK, SCHÖNEWOLF-GREULICH B, MOUTTON S, LAURITANO A, NAPPI P, SOLDVIERI MV, SCHEFFER IE, MEFFORD HC, STONG N, HEINZEN EL, GOLDSTEIN DB, PEREZ AG, KOSSOFF EH, STOCCO A, SULLIVAN JA, SHASHI V, GERARD B, FRANCCANNET C, BISGAARD AM, TÜMER Z, WILLEMS M, RIVIER F, VITOBELLO A, THAKKAR K, RAJAN DS, BARKOVICH AJ, WECKHUYSEN S, COOPER EC, TAGLIALATELA M, CILIO MR. Autism and developmental disability caused by KCNQ3 gain-of-function variants. **Ann Neurol.** 86:181-192, 2019.
3. DILENA R, DIFRANCESCO JC, SOLDVIERI MV, GIACOBBE A, AMBROSINO P, MOSCA I, GALLI MA, GUEZ S, FUMAGALLI M, MICELI F, CATTANEO D, DARRA F, GENNARO E, ZARA F, STRIANO P, CASTELLOTTI B, GELLERA C, VARESIO C, VEGGIOTTI P, TAGLIALATELA M. Early Treatment with Quinidine in 2 Patients with Epilepsy of Infancy with Migrating Focal Seizures (EIMFS) Due to Gain-of-Function KCNT1 Mutations: Functional Studies, Clinical Responses, and Critical Issues for Personalized Therapy. **Neurotherapeutics.** 15:1112-1126, 2018.
4. AMBROSINO P, SOLDVIERI MV, BAST T, TURNPENNY PD, UHRIG S, BISKUP S, DÖCKER M, FLECK T, MOSCA I, MANOCCHIO L, IRACI N, TAGLIALATELA M, LEMKE JR. De novo gain-of-function variants in KCNT2 as a novel cause of developmental and epileptic encephalopathy. **Ann Neurol.** 83:1198-1204, 2018.
5. MICELI F, SOLDVIERI MV, AMBROSINO P, DE MARIA M, MIGLIORE M, MIGLIORE R, TAGLIALATELA M. Early-Onset Epileptic Encephalopathy Caused by Gain-of-Function Mutations in the Voltage Sensor of Kv7.2 and Kv7.3 Potassium Channel Subunits. **J Neurosci.** 35:3782-93, 2015.